What happens when you take cbd with simvastatin?
Simvastatin is one of the most CYP3A4-sensitive statins on the market. It undergoes extensive first-pass metabolism in the gut wall and liver, primarily via CYP3A4, before being converted to its active beta-hydroxyacid form. Because the pre-systemic loss is so large, even modest CYP3A4 inhibition can produce out-of-proportion increases in systemic simvastatin exposure - this is why grapefruit juice, ketoconazole, and erythromycin all carry strong warnings on the simvastatin label.
Cannabidiol (CBD) is an established CYP3A4 inhibitor at clinically used doses. The FDA Epidiolex prescribing information specifically cautions that CBD can increase the exposure of CYP3A4 substrates and recommends considering a dose reduction of sensitive CYP3A4 substrates when co-administered with cannabidiol. While head-to-head pharmacokinetic studies of CBD with simvastatin are limited compared to the clobazam data, the mechanism is well established and consistent with what is seen when other CYP3A4 inhibitors are added to simvastatin.
Why is this important?
Statin-related muscle problems span a spectrum from mild myalgia to disabling myopathy to life-threatening rhabdomyolysis with acute kidney injury. The risk is dose-dependent: higher simvastatin levels mean higher risk of muscle injury and transaminase elevation. The simvastatin label already restricts the maximum dose with certain CYP3A4 inhibitors and outright contraindicates use with strong inhibitors like itraconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, cobicistat-containing products, boceprevir, telaprevir, nefazodone, and gemfibrozil. CBD is not in that contraindicated list, but it is a moderate CYP3A4 inhibitor, and the risk arrow points the same direction.
The interaction is most relevant for patients on higher simvastatin doses (40-80 mg/day), for older adults, for patients of East Asian ancestry (who have lower threshold for simvastatin toxicity), for those with hypothyroidism, kidney disease, or vitamin D deficiency, and for those also taking other CYP3A4-affecting drugs (amlodipine, diltiazem, verapamil, amiodarone) or grapefruit products. Because CBD is widely sold over-the-counter and many patients use it for sleep or musculoskeletal complaints - the same demographic taking statins - the overlap is common in practice.
What should you do?
The combination is manageable but should be a deliberate choice, not an accidental one.
- Tell the prescriber about any CBD use before starting or escalating simvastatin, and before adding CBD to existing simvastatin therapy.
- Consider switching statins. Pravastatin and rosuvastatin are minimally metabolized by CYP3A4 and are much less affected by CYP3A4 inhibitors; for many patients, a switch is the simplest fix.
- If staying on simvastatin, ask about a lower dose (for example, capping at 20 mg/day rather than 40-80 mg) when concomitant CBD is anticipated.
- Avoid stacking inhibitors: grapefruit/grapefruit juice, amlodipine at high doses, diltiazem, verapamil, amiodarone, and macrolide antibiotics like clarithromycin all add to the CYP3A4 burden.
- Report new muscle symptoms promptly: aching, weakness, tenderness, brown or cola-colored urine, or fatigue out of proportion to activity. These warrant a CK (creatine kinase) check and a clinical evaluation.
- Baseline and periodic liver enzymes are reasonable when both agents are used long-term.
Which specific products are affected?
Simvastatin is sold as Zocor, Flolipid, and many generics; combination pills such as Vytorin (ezetimibe/simvastatin) and Simcor (niacin/simvastatin) contain simvastatin and behave the same. The CBD interaction is a class effect across pharmaceutical Epidiolex (cannabidiol oral solution) and consumer CBD products - oils, tinctures, gummies, capsules, vapes, beverages, and sublingual sprays. Full-spectrum hemp products that contain THC and other minor cannabinoids may add further CYP3A4 inhibition. Atorvastatin and lovastatin are also CYP3A4 substrates and would behave similarly, though atorvastatin is somewhat less sensitive. Pravastatin, rosuvastatin, and pitavastatin are far less CYP3A4-dependent and are reasonable alternatives in patients committed to CBD use.
The bottom line
CBD inhibits CYP3A4 and can raise simvastatin levels, increasing the risk of muscle pain, myopathy, transaminase elevation, and rare rhabdomyolysis. The interaction is mechanistically well established and reflected in CYP3A4-substrate language on the Epidiolex label. If you take simvastatin and want to use CBD, talk to the prescriber about a dose adjustment, a switch to a less CYP3A4-sensitive statin, and watch for new muscle symptoms.